Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome
Clinical Cardiology · 2025-12 · 48 (12)
DOI: 10.1002/clc.70232 ↗At a glance
Journal article in Clinical Cardiology, published online on 2025-12-11. Written by Yanming Zhang and 5 co-authors. Institution: Department of Cardiology, Changhai Hospital, Naval Military Medical University, Shanghai, Yangpu, People's Republic of China. Major MEDLINE topics: Ticagrelor, Acute Coronary Syndrome, Cytochrome P-450 CYP3A, Polymorphism, Single Nucleotide. Cited 2 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY 4.0). Funded by: Naval Medical University Medical New Technology Cultivation Project, Efficacy Prediction and Patient Screening Strategy for CCM Based on the Levosimendan Treatment Response Rate in Heart Failure Patients, Mechanism Study on Improving Post-Myocardial Infarction Cardiac Function by Knocking Down DNM3OS to Target TFAM and Promote Myocardial Mitochondrial Gene Expre….
Abstract (original language)
Background
Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor is standard for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. While ticagrelor offers superior efficacy in reducing ischemic events compared to clopidogrel, its use is limited by a higher incidence of dyspnea, an adverse reaction whose underlying predictors remain incompletely understood. Genetic variations in CYP3A4/5, the principal enzymes responsible for ticagrelor metabolism, may influence interindividual susceptibility to this side effect.
Methods
In a prospective cohort of 385 ACS patients on ticagrelor, we genotyped CYP3A4 rs2242480 and CYP3A5 rs776746. Outcomes (dyspnea per CTCAE v5.0, bleeding per BARC criteria) were assessed over 1 year. Associations were analyzed using logistic regression and GMDR modeling.
Results
The CYP3A5 rs776746 genotype strongly predicted dyspnea risk. Compared to the CC genotype, CT and TT genotypes were associated with a 55% and 91% reduced risk, respectively. Carriers of the combined CT/TT genotypes had a 63% lower risk. CC genotype carriers (poor metabolizers) exhibited a 2.3‐fold higher dyspnea incidence. No significant associations were found for CYP3A4 rs2242480 or for bleeding outcomes.
Conclusion
The CYP3A5 rs776746 CC genotype is a significant genetic biomarker for ticagrelor‐induced dyspnea. Pre‐emptive genotyping could enable personalized antiplatelet therapy, such as alternative P2Y₁₂ inhibitors for high‐risk CC carriers, to improve patient safety.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Cardiology, Changhai Hospital, Naval Military Medical University, Shanghai, Yangpu, People's Republic of China.
ORCID profiles: Yanming Zhang
Funding
- Naval Medical University Medical New Technology Cultivation Project
- Efficacy Prediction and Patient Screening Strategy for CCM Based on the Levosimendan Treatment Response Rate in Heart Failure Patients
- Mechanism Study on Improving Post-Myocardial Infarction Cardiac Function by Knocking Down DNM3OS to Target TFAM and Promote Myocardial Mitochondrial Gene Expre…
- Naval Medical University Youth Cultivation Project
- The Function and Mechanism of TTP in Mediating TNFα and GM-CSF mRNA Degradation and Translation Inhibition via AU-rich Elements to Attenuate Cardiomyocyte Apop…
Cite
APA
Zhang, Y., Yu, G., Wang, C., Song, J., Liu, J., & Chen, F. (2025). Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. Clinical Cardiology, 48(12). https://doi.org/10.1002/clc.70232
Vancouver
Zhang Y, Yu G, Wang C, Song J, Liu J, Chen F. Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. Clinical Cardiology. 2025;48(12). doi:10.1002/clc.70232
BibTeX
@article{Zhang2025,
author = {Zhang, Yanming and Yu, Gaoxiu and Wang, Cong and Song, Jingwen and Liu, Junmei and Chen, Feng},
title = {Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome},
journal = {Clinical Cardiology},
year = {2025},
volume = {48},
number = {12},
doi = {10.1002/clc.70232}
}
EUVIMED